- Home
- MIRM
as 10-29-2025 9:33am EST
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as Mirum Pharmaceuticals Inc. MIRM prepares to release earnings report on 04 Nov 2025.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 3.8B | IPO Year: | 2019 |
| Target Price: | $79.00 | AVG Volume (30 days): | 600.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.88 - $78.55 | Next Earning Date: | 11-04-2025 |
| Revenue: | $429,161,000 | Revenue Growth: | 62.33% |
| Revenue Growth (this year): | 53.14% | Revenue Growth (next year): | 19.83% |
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ramasastry Saira | MIRM | Director | Sep 8 '25 | Sell | $0.00 | 17,000 | $0.00 | 0 | |
| BJERKHOLT ERIC | MIRM | CHIEF FINANCIAL OFFICER | Aug 11 '25 | Sell | $0.00 | 8,000 | $0.00 | 28,236 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Aug 11 '25 | Sell | $62.00 | 40,000 | $2,480,000.00 | 138,641 |
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
Business Wire
19 days ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
TD Cowen Initiates Mirum Pharmaceuticals at Buy With $95 Price Target
Simply Wall St.
a month ago
Loss-Making Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Expected To Breakeven In The Medium-Term
Business Wire
2 months ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor's Business Daily
4 months ago
Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up
Investor's Business Daily
5 months ago
CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner
Simply Wall St.
5 months ago
High Growth Tech Stocks In The US Market
Zacks
5 months ago
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Compare MIRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.